Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, +13

Haematologica

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia

Simone Claudiani, Jane F. Apperley, Richard Szydlo, +9

British Journal of Haematology

Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance

Simone Claudiani, Farhan Chughtai, Afzal Khan, +8

Leukemia

Durable humoral responses after the second anti‐SARS‐CoV‐2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors

Simone Claudiani, Jane F. Apperley, Eleanor Parker, +7

British Journal of Haematology

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies

Lucy Cook, Gillian O’Dell, Eleni Vourvou, +15

Nature Communications

Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score

Fiona Fernando, María Sol Andrés, Simone Claudiani, +8

Cardio-Oncology

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

Simone Claudiani, Aoife Gatenby, Richard Szydlo, +8

Haematologica

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia

Simone Claudiani, Carolina Rosadas, Myra O. McClure, +5

Blood

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous <i>BCR-ABL1</i> kinase domain mutations

Simone Claudiani, Jane F. Apperley, Afzal Khan, +2

Haematologica

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, Silvia Metelli, Rafiee Kamvar, +13

Blood